COMMUNICATION
Feedback Regulation of beta -Arrestin1 Function by Extracellular Signal-regulated Kinases*

Fang-Tsyr Lin, William E. Miller, Louis M. Luttrell, and Robert J. LefkowitzDagger

From the Howard Hughes Medical Institute, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27710

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The functions of beta -arrestin1 to facilitate clathrin-mediated endocytosis of the beta 2-adrenergic receptor and to promote agonist-induced activation of extracellular signal-regulated kinases (ERK) are regulated by its phosphorylation/dephosphorylation at Ser-412. Cytoplasmic beta -arrestin1 is almost stoichiometrically phosphorylated at Ser-412. Dephosphorylation of beta -arrestin1 at the plasma membrane is required for targeting a signaling complex that includes the agonist-occupied receptors to the clathrin-coated pits. Here we demonstrate that beta -arrestin1 phosphorylation and function are modulated by an ERK-dependent negative feedback mechanism. ERK1 and ERK2 phosphorylate beta -arrestin1 at Ser-412 in vitro. Inhibition of ERK activity by a dominant-negative MEK1 mutant significantly attenuates beta -arrestin1 phosphorylation, thereby increasing the concentration of dephosphorylated beta -arrestin1. Under such conditions, beta -arrestin1-mediated beta 2-adrenergic receptor internalization is enhanced as is its ability to bind clathrin. In contrast, if ERK-mediated phosphorylation is increased by transfection of a constitutively active MEK1 mutant, receptor internalization is inhibited. Our results suggest that dephosphorylated beta -arrestin1 mediates endocytosis-dependent ERK activation. Following activation, ERKs phosphorylate beta -arrestin1, thereby exerting an inhibitory feedback control of its function.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The life cycle of G protein-coupled receptors (GPCRs)1 includes receptor activation, desensitization, sequestration, and either resensitization (recycling) or degradation (1). beta -Arrestins were initially discovered as molecules that bind to agonist-occupied receptors following receptor phosphorylation by G protein-coupled receptor kinases, thereby interdicting signal transduction to G proteins and causing receptor desensitization (2, 3). More recently, however, beta -arrestins have been shown to be involved in the internalization and signaling of GPCRs (4). For example, they serve as clathrin adaptors, which help to target agonist-occupied GPCRs to clathrin-coated pits for internalization (5). This function is regulated by phosphorylation/dephosphorylation of beta -arrestin1 at a carboxyl-terminal serine, Ser-412 (6). Cytosolic beta -arrestin1 is constitutively phosphorylated by heretofore unidentified kinase(s) and is rapidly dephosphorylated when it is recruited to the plasma membrane in response to agonist stimulation. Dephosphorylation of beta -arrestin1 at the plasma membrane is not required for receptor binding and receptor desensitization but is required for its clathrin binding and receptor internalization. The S412A mutant of beta -arrestin1, which mimics the dephosphorylated form, has been shown to be more active than wild-type beta -arrestin1 in promoting clathrin-mediated endocytosis of the beta 2-adrenergic receptor. In contrast, the S412D mutant, which simulates the phosphorylated form of beta -arrestin1, acts as a dominant-negative inhibitor of receptor endocytosis (6). Moreover, in addition to regulating the internalization of classical GPCRs, such as the beta 2-adrenergic receptor, beta -arrestin1 has been shown to bind to the tyrosine kinase insulin-like growth factor I receptor and mediate its endocytosis in an analogous fashion (7).

Recently, several studies have shown that clathrin-mediated internalization is required for mitogenic signaling by various GPCRs and tyrosine kinase growth factor receptors (7-12, 15). Thus, inhibition of clathrin-mediated internalization reduces agonist-induced activation of ERK1 and 2. The Ras-dependent activation of ERKs by GPCRs also requires c-Src (13, 14). Very recently, it has been shown that beta -arrestins serve to recruit the activated c-Src to the agonist-occupied beta 2-adrenergic receptors as well as to target this signaling complex to the clathrin-coated pits for internalization and activation of the ERK cascade (15). Like clathrin targeting, the recruitment and activation of c-Src kinase is modulated by phosphorylation/dephosphorylation of beta -arrestin1 (15). The S412D beta -arrestin1 mutant, defective in both binding to Src and targeting the receptors to clathrin-coated pits, acts as a dominant-negative inhibitor of agonist-induced ERK activation. In contrast, the S412A beta -arrestin1 mutant, which binds to Src as well as the wild-type beta -arrestin1, is active in promoting agonist-induced ERK phosphorylation.

ERK activity appears to be tightly regulated by an activation/inactivation cycle. GPCR-mediated activation of ERKs involves the sequential involvement of components of a Ras activation complex, including c-Src, Shc, Grb2, Gab1, and Sos1, followed by activation of Raf-1 kinase and MEK1 (13, 14). It has been shown that the inactivation of this cascade is associated with the induction of mitogen-activated protein kinase phosphatase (MKP-1) by agonist stimulation (16). Previous studies also suggest that it may involve the negative feedback phosphorylation of upstream activators, including Sos1, Raf-1 kinase, and MEK1, by the activated ERK (17-21). Recently ERK has been reported to phosphorylate IRS-1 and reduce its function, thereby inhibiting further insulin signaling (22). These findings underscore the requirement for stringent control of cellular ERK activity by feedback regulatory mechanisms. Here we demonstrate a novel form of feedback regulation controlling GPCR-mediated activation of ERKs. Once stimulated, the ERKs phosphorylate beta -arrestin1 at Ser-412, thereby reducing its endocytic functions and thus ultimately reducing ERK activation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Expression of beta -Arrestin1 in Escherichia coli and Phosphorylation in Vitro-- A 1.26-kilobase KpnI/HindIII fragment encoding (S412D)beta arr1-His6 was removed from pBS/(S412D)beta arr1-His6 (6) and subcloned into pKK223-3 vector (Amersham Pharmacia Biotech). After transfection of pKK/beta arr1-His6 or pKK/(S412D)beta arr1-His6 plasmid into E. coli, expression of the proteins was induced by isopropyl-1-thio-beta -D-galactopyranoside. beta -Arrestin1 was purified by nickel affinity chromatography followed by Heparin-Sepharose chromatography as described before (6). 20 pmol of wild-type or S412D beta -arrestin1 were incubated with either 0.9 µg of GST-ERK1 (Upstate Biotechnologies Inc.), 0.15 µg of ERK2 (Upstate Biotechnologies Inc.), or 10 units of GSK-3 (New England Biolabs) in the presence of 20 mM Tris, pH 7.4, 2 mM EDTA, 10 mM MgCl2, 1 mM dithiothreitol, 100 µM ATP, and 1 µCi of [gamma -32P]ATP at 30 °C for 30 min. The phosphoproteins were fractionated by SDS-PAGE. The gel was dried and developed by autoradiography.

Two-dimensional Tryptic Phosphopeptide Mapping-- Purified phospho-beta -arrestin1 (wild-type or S412D) was resolved by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Immobilon, Millipore). The phospho-beta -arrestin1 band was cut out, digested with trypsin in situ, and oxidized in performic acid (23). Lyophilized peptides were resolved by electrophoresis at pH 3.5 in the first dimension and ascending chromatography in the second dimension as described (24). Phosphopeptides were detected by autoradiography.

Metabolic Labeling-- The His-tagged beta -arrestin1 expression vector was transfected alone or with the dominant-negative MEK1(K97A) plasmid (25) into HEK 293 cells. Cells were labeled with [32P]orthophosphate for 1 h and then harvested for beta -arrestin1 purification as described (6).

Co-immunoprecipitation and Immunoblotting-- The FLAG-tagged beta -arrestin1 expression vector was transfected alone or with the MEK1(K97A) plasmid into HEK 293 cells. Two days after transfection, cells were harvested and lysed for co-immunoprecipitation as described (6). The FLAG-tagged beta -Arrestin1 (15) was immunoprecipitated with a polyclonal antibody directed against the FLAG epitope (Santa Cruz Inc.). After SDS-PAGE, the immunoblot was probed with a monoclonal antibody specific to clathrin heavy chain (Transduction Laboratories) and was visualized by enhanced chemiluminescence assay (ECL, Amersham Pharmacia Biotech). The expression levels of phospho-ERKs, total cellular ERKs, and MEK1 mutants (K97A and S218D/S222D) (25, 26) in whole cell extracts were determined by probing the immunoblots separately with the antibodies specific to phospho-ERK (Promega), cellular ERK2 (Transduction Laboratories), or MEK1 (Transduction Laboratories).

Agonist-promoted Sequestration of the beta 2-Adrenergic Receptors-- HEK 293 cells were transiently transfected with the plasmid encoding FLAG-tagged beta 2-adrenergic receptors with or without the expression vectors of beta -arrestin and a MEK1 mutant. Two days after transfection, cells were incubated with 10 µM (-)-isoproterenol in 0.1 mM ascorbic acid for 30 min before harvesting. The agonist-promoted sequestration of beta 2-adrenergic receptors was determined by immunofluorescence flow cytometry as described previously (27).

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

ERKs Phosphorylate beta -Arrestin1 at Ser-412 in Vitro-- Previously we have shown that cytosolic beta -arrestin1 is highly phosphorylated and is dephosphorylated only when it is recruited to the plasma membrane in response to agonist stimulation (6). The major phosphorylation site is located at the carboxyl-terminal Ser-412, which accounts for 90% of beta -arrestin1 phosphorylation. To identify the candidate kinase(s) that phosphorylate beta -arrestin1 at Ser-412, we tested the ability of several kinases to phosphorylate beta -arrestin1 in vitro. Because Ser-412 is followed by a proline residue, a consensus phosphorylation sequence recognized by members of the mitogen-activated protein kinase family as well as by glycogen synthase kinase-3 (GSK-3), we speculated that these kinases might be potential candidates for mediating Ser-412 phosphorylation. Therefore, equal amounts of wild-type and S412D beta -arrestin1 purified from E. coli were subjected to phosphorylation by ERK1, ERK2, or GSK-3 in vitro. As shown in Fig. 1, wild-type beta -arrestin1 was highly phosphorylated by either ERK1 or ERK2. The stoichiometry was ~0.8 mol of Pi/mol of protein. Mutation of Ser-412 to Asp markedly reduced ERK-mediated beta -arrestin1 phosphorylation. Both wild-type and S412D beta -arrestin1 were equally but weakly phosphorylated by GSK-3, indicating that GSK-3 is not the kinase responsible for Ser-412 phosphorylation.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Phosphorylation of beta -arrestin1 by ERK1, ERK2, and GSK-3 in vitro. 20 pmol of His-tagged wild-type (WT) or S412D beta -arrestin1 purified from E. coli were phosphorylated in vitro by ERK1, ERK2, or GSK-3 in the presence of [gamma -32P]ATP as described under "Experimental Procedures." The phosphoproteins were fractionated by SDS-PAGE. The gel was dried and developed by autoradiography.

Next, we compared the two-dimensional tryptic phosphopeptide map of cellular beta -arrestin1 with those of wild-type and S412D beta -arrestin1 phosphorylated by ERK2 in vitro. As shown in Fig. 2A, the two-dimensional phosphopeptide mapping of cellular beta -arrestin1 purified from HEK 293 cells indicates that it contains three phosphopeptides: a1, a2, and b. The major phosphopeptides, a1 and a2, are partial digestion products (amino acids 401-418 and 398-418) containing Ser-412 (Fig. 2B) as confirmed by amino acid sequencing (6). The two-dimensional phosphopeptide map of beta -arrestin1 phosphorylated by ERK2 in vitro (Fig. 2C) was identical with the pattern derived from cellular phospho-beta -arrestin1. This was further confirmed by the identical map derived from a mixture of equal amounts of cellular phospho-beta -arrestin1 and ERK2-phosphorylated beta -arrestin1 (data not shown). These two phosphopeptides, a1 and a2, were missing in the map of S412D beta -arrestin1 phosphorylated by ERK2 (Fig. 2D). Taken together, our results indicate that ERK is capable of phosphorylating Ser-412 of beta -arrestin1. Although beta -arrestin1 could be phosphorylated by protein kinases A and C, GRK2, and casein kinase I and II in vitro, in no case did the two-dimensional tryptic phosphopeptide maps match those of beta -arrestin1 purified from cells (data not shown). Moreover, mutation of Ser-412 to Asp did not reduce in vitro phosphorylation of beta -arrestin1 by these kinases, indicating that these kinases are not responsible for Ser-412 phosphorylation.


View larger version (90K):
[in this window]
[in a new window]
 
Fig. 2.   Two-dimensional tryptic phosphopeptide mapping of cellular phospho-beta -arrestin1 and ERK2-phosphorylated beta -arrestin1. A, 32P-labeled beta -arrestin1 (beta arr1) was purified from HEK 293 cells overexpressing His-tagged beta -arrestin1, resolved by SDS-PAGE, and transferred to Immobilon polyvinylidene difluoride membranes. The 32P-labeled beta -arrestin1 was cut out, digested with trypsin, resolved in two dimensions by electrophoresis and chromatography, and detected by autoradiography. × is the origin of sample loading. The arrows indicate the major partially digested phosphopeptides a1 and a2 and the minor phosphopeptide b. B, tryptic phosphopeptides as described above were purified by reverse-phase high pressure liquid chromatography. Two major phosphopeptides identified as amino acids 401-418 and 398-418 (6) were mixed and subjected to two-dimensional phosphopeptide mapping analysis. C and D, ERK-phosphorylated wild-type (C) and S412D (D) beta -arrestin1 as described in Fig. 1 were digested with trypsin and subjected to two-dimensional phosphopeptide mapping analysis as described.

Inhibition of beta -Arrestin1 Phosphorylation in HEK 293 Cells by a Dominant-negative MEK1 Inhibitor-- To investigate whether ERK1 and ERK2 mediate beta -arrestin1 phosphorylation in cells, we employed a dominant-negative MEK1(K97A) inhibitor (25) to determine whether inhibition of ERK activity might affect beta -arrestin1 phosphorylation. Overexpression of the MEK1(K97A) mutant in HEK 293 cells significantly reduced ERK phosphorylation (Fig. 3, lower panel). This was associated with ~70% reduction of beta -arrestin1 phosphorylation (Fig. 3, upper panel). Increasing the level of activated ERKs with a constitutively active S218D/S222D mutant of MEK1 (26) did not significantly elevate beta -arrestin1 phosphorylation (data not shown), consistent with the high stoichiometry of cellular phosphorylation of beta -arrestin1 at Ser-412 (0.85 mol Pi/mol protein) (6). These results demonstrate that inhibition of ERK activation blocks beta -arrestin1 phosphorylation in HEK 293 cells, thus further implicating ERKs as the kinases responsible for phosphorylating beta -arrestin1 in cells.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of the dominant-negative MEK1(K97A) mutant on phosphorylation of beta -arrestin1 in HEK 293 cells. HEK 293 cells, transiently expressing His-tagged beta -arrestin1 alone or with MEK1(K97A), were split onto two plates each. Upper panel, one plate was metabolically labeled with [32P]orthophosphate for 1 h. beta -Arrestin1 was purified, resolved by SDS-PAGE, and transferred to nitrocellulose membranes. After autoradiography, this membrane was subjected to Western blot analysis using an antibody specific to beta -arrestin1. Lower panel, equal amounts of whole cell lysates from the other plate were fractionated by SDS-PAGE and subjected to Western blot analysis using a specific anti-phospho-ERK antibody. This blot was then stripped and reprobed with an ERK2 antibody to ensure equal expression of total cellular ERKs. Overexpression of MEK1(K97A) was detected by an antibody specific to MEK1.

Regulation of beta -Arrestin1 Function by Constitutively Active and Dominant-negative Mutants of MEK1-- Previously we have shown that dephosphorylation of beta -arrestin1 at the plasma membrane is required for clathrin binding and agonist-induced internalization of the beta 2-adrenergic receptor (6). Thus, it would be expected that increasing the level of dephosphorylated beta -arrestin1 in cells by inhibiting ERK activation with the dominant-negative MEK1(K97A) mutant would augment its clathrin binding ability and function in receptor internalization. As shown in Fig. 4A, the dominant-negative MEK1(K97A) mutant significantly enhances the co-immunoprecipitation of wild-type beta -arrestin1 with clathrin heavy chain. The S412A mutant of beta -arrestin1, which mimics the dephosphorylated form of beta -arrestin1, also robustly co-immunoprecipitated clathrin (Fig. 4A). We did not observe any effect of the constitutively active S218D/S222D mutant of MEK1 on clathrin binding of beta -arrestin1 (data not shown), presumably because cellular beta -arrestin1 is already so highly phosphorylated that we could not detect its binding with clathrin.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of MEK1 mutants on clathrin binding ability of beta -arrestin1 and beta -arrestin-mediated sequestration of the beta 2-adrenergic receptors. A, HEK 293 cells were transiently transfected with either an empty vector (mock), a FLAG-tagged beta -arrestin1 expression vector (beta arr1 or S412A) or co-transfected with the FLAG-tagged beta -arresitn1 and MEK1(K97A) plasmids. Equal amounts of proteins from the whole cell lysates were immunoprecipitated (IP) with an antibody directed at the FLAG epitope. After SDS-PAGE, the immunoblot was probed with an antibody specific to clathrin heavy chain (HC) as shown on the top panel. The lower four panels are the immunoblots from 5% of the whole cell lysates probed with the antibodies specific to either MEK1, phospho-ERKs, total cellular ERK2, or beta -arrestin1. B, the beta 2-adrenergic receptor (beta 2-AR) expression plasmid was transiently transfected into HEK 293 cells with a beta -arrestin expression vector (mock, beta arr1, or beta arr2) and a MEK1 mutant expression vector (empty vector, dominant-negative K97A, or constitutively active S218D/S222D). Cells were incubated with or without (-) isoproterenol (ISO) for 30 min before harvesting. The assay of agonist-promoted receptor sequestration was carried out as described. The results shown are the means ± S.E. of three independent experiments done in duplicate. At the right lower corner is a representative Western blot showing the expression levels of phospho-ERKs and MEK1 mutants in the presence of MEK1(K97A) or MEK1(S218D/S222D).

We further investigated the effect of dominant-negative K97A and constitutively active S218D/S222D mutants of MEK1 on beta -arrestin1-mediated sequestration of the beta 2-adrenergic receptors. In the presence of the MEK1(K97A) mutant, receptor sequestration was increased in control HEK 293 cells. It was further promoted by overexpressing beta -arrestin1 (Fig. 4B), presumably because the level of active, dephosphorylated beta -arrestin1 is highly increased by MEK1(K97A) mutant (as it is by S412A beta -arrestin1 (6)). In contrast, the constitutively active S218D/S222D mutant of MEK1 slightly reduced receptor sequestration in control cells. This reduction was even more dramatic in cells overexpressing beta -arrestin1 where receptor sequestration was now predominantly mediated by transfected beta -arrestin1 (in contrast to control cells where both endogenous beta -arrestin1 and 2 participate). In such cells, levels of the phosphorylated beta -arrestin1 are increased to such high levels by the constitutively active MEK1 mutant that phospho-beta -arrestin1 now acts essentially as a dominant-negative inhibitor of receptor internalization (as does S412D beta -arrestin1 (6)).

To determine whether the effect of MEK mutants was specifically due to altered beta -arrestin1 function, we also tested their effects on receptor sequestration mediated by beta -arrestin2. Interestingly, this enhancement was not significantly affected by either MEK1 mutant in cells overexpressing beta -arrestin2 (Fig. 4B). This result suggests that ERKs can modulate the function of beta -arrestin1 but not beta -arrestin2. Although beta -arrestin2 is also a phosphoprotein in cells (data not shown), it has no site corresponding to Ser-412 of beta -arrestin1. This suggests that ERKs are not the kinases that phosphorylate beta -arrestin2 in cells.

A Model for Negative Feedback Regulation of beta -Arrestin1 Function by ERK-mediated Phosphorylation-- Fig. 5 provides a model for the feedback regulation of beta -arrestin1 function by ERK-mediated phosphorylation of Ser-412. Cytosolic beta -arrestin1, which is predominately phosphorylated at Ser-412 (6), is recruited to the plasma membrane upon agonist stimulation. Membrane-bound beta -arrestin1 is dephosphorylated by as yet unknown phosphatases. Although dephosphorylation of beta -arrestin1 is not required for its receptor binding, it is required for several of its other functions including Src recruitment (15) and clathrin binding (6). These events in turn are necessary for GPCR-mediated activation of the Ras-dependent ERK pathway (13). Once activated, the ERKs are able to phosphorylate beta -arrestin1 at Ser-412, thereby reducing these functions and, in a feedback regulatory fashion, reducing further ERK signaling.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 5.   A model for the negative feedback regulation of beta -arrestin1 function by ERK-mediated phosphorylation. Cytosolic beta -arrestin1 is predominantly phosphorylated at Ser-412. It is dephosphorylated when recruited to the plasma membrane in response to agonist stimulation. Dephosphorylated beta -arrestin1 binds to Src and also targets the agonist-occupied, GRK-phosphorylated GPCR to the clathrin-coated pits for internalization. ERK is activated subsequent to the receptor internalization event. Afterward, the activated ERK phosphorylates beta -arrestin1 at Ser-412, reduces its ability to bind Src (15) and clathrin (6), and thereby attenuates ERK signaling. Ultimately the receptors are dephosphorylated and recycled back to the plasma membrane for resensitization. A, agonist; GRK2, G protein-coupled receptor kinase 2; (+), stimulatory effect; (-), inhibitory effect.


    ACKNOWLEDGEMENTS

The model shown in this paper was kindly provided by Dr. Stuart Maudsley. The expression vectors of MEK1(K97A) and MEK1(S218D/S222D) mutants were generous gifts from Dr. Edwin G. Krebs and Dr. Raymond. L. Erikson, respectively. We thank Drs. Yehia Daaka, Julie A. Pitcher, and Randy Hall for helpful discussions. We also thank Donna Addison and Mary Holben for excellent secretarial assistance.

    FOOTNOTES

* This work was supported by the Howard Hughes Medical Institute and by Grant HL16037 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Investigator of the Howard Hughes Medical Institute. To whom correspondence should be addressed: Howard Hughes Medical Inst., Dept. of Medicine and Biochemistry, Duke University Medical Center, Box 3821, Durham, NC 27710. E-mail: lefko001{at}mc.duke.edu.

    ABBREVIATIONS

The abbreviations used are: GPCR, G protein-coupled receptor; ERK, extracellular signal-regulated kinase(s); PAGE, polyacrylamide gel electrophoresis.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
  1. Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 18677-18680[Free Full Text]
  2. Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1990) Science 248, 1547-1550[Medline] [Order article via Infotrieve]
  3. Attramadal, H., Arriza, J. L., Aoki, C., Dawson, T. M., Codina, J., Kwatra, M. M., Snyder, S. H., Caron, M. G., and Lefkowitz, R. J. (1992) J. Biol. Chem. 267, 17882-17890[Abstract/Free Full Text]
  4. Ferguson, S. S. G., Downey, W. E., III, Colapietro, A.-M., Barak, L. S., Menard, L., and Caron, M. G. (1996) Science 271, 363-366[Abstract]
  5. Goodman, O. B., Jr., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1996) Nature 383, 447-450[CrossRef][Medline] [Order article via Infotrieve]
  6. Lin, F.-T., Krueger, K. K., Kendall, H. E., Daaka, Y., Fredericks, Z. L., Pitcher, J. A., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 31051-31057[Abstract/Free Full Text]
  7. Lin, F.-T., Daaka, Y., and Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 31640-31643[Abstract/Free Full Text]
  8. Vieira, A. V., Lamaze, C., and Schmid, S. L. (1996) Nature 274, 2086-2089
  9. Riccio, A., Pierchala, B. A., Ciarallo, C. L., and Ginty, D. D. (1997) Science 277, 1097-1100[Abstract/Free Full Text]
  10. Chow, J. C., Condorelli, G., and Smith, R. J. (1998) J. Biol. Chem. 273, 4672-4680[Abstract/Free Full Text]
  11. Luttrell, L. M., Daaka, Y., Della Rocca, G. J., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 31648-31656[Abstract/Free Full Text]
  12. Daaka, Y., Luttrell, L. M., Ahn, S., Della Rocca, G. J., Ferguson, S. S. G., Caron, M. G., and Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 685-688[Abstract/Free Full Text]
  13. van Biesen, T., Luttrell, L. M., Hawes, B. E., and Lefkowitz, R. J. (1996) Endocr. Rev. 17, 698-714[Medline] [Order article via Infotrieve]
  14. Gutkind, J. S. (1998) J. Biol. Chem. 273, 1839-1842[Free Full Text]
  15. Luttrell, L. M., Ferguson, S. S., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F.-T., Kawakatsu, H., Owada, K., Luttrell, D. K., Caron, M. G., and Lefkowitz, R. J. (1999) Science 283, 655-661[Abstract/Free Full Text]
  16. Charles, C. H., Sun, H., lau, L. F., and Tonks, N. K. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5292-5296[Abstract]
  17. Profiri, E., and McCormick, F. (1996) J. Biol. Chem. 271, 5871-5877[Abstract/Free Full Text]
  18. Foschi, M., Chari, S., Dunn, M. J., and Sorokin, A. (1997) EMBO J. 16, 6439-6451[Abstract/Free Full Text]
  19. Lee, R., Cobb, M. H., and Blackshear, P. J. (1992) J. Biol. Chem. 267, 1088-1092[Abstract/Free Full Text]
  20. Ueki, K., Matsuda, S., Tobe, K., Gotoh, Y., Tamemoto, H., Yachi, M., Akanuma, Y., Yazaki, Y., Nishida, E., and Kadowaki, T. (1994) J. Biol. Chem. 269, 15756-15761[Abstract/Free Full Text]
  21. Brunet, A., Pages, G., and Pouyssegur, J. (1994) FEBS Lett. 346, 299-303[CrossRef][Medline] [Order article via Infotrieve]
  22. De Fea, K., and Roth, R. A. (1997) J. Biol. Chem. 272, 31400-31406[Abstract/Free Full Text]
  23. Luo, K., Hurley, T. R., and Sefton, B. M. (1991) Methods Enzymol. 201, 149-152[Medline] [Order article via Infotrieve]
  24. Huganir, R. L., Miles, K., and Greengard, P. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 6968-6972[Abstract]
  25. Seger, R., Seger, D., Reszka, A. A., Munar, E. S., Eldar-Finkelman, H., Dobrowolska, G., Jensen, A. M., Campbell, J. S., Fischer, E. H., and Krebs, E. G. (1994) J. Biol. Chem. 269, 25699-25709[Abstract/Free Full Text]
  26. Huang, W., Kessler, D. S., and Erikson, R. L. (1995) Mol. Biol. Cell 6, 237-245[Abstract]
  27. Barak, L. S., Tiber, M., Freedman, N. J., Kwatra, M. M., Lefkowitz, R. J., and Caron, M. G. (1994) J. Biol. Chem. 269, 2790-2795[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.